02:59:37 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2025-02-14 Bokslutskommuniké 2024
2024-11-14 Kvartalsrapport 2024-Q3
2024-08-16 Kvartalsrapport 2024-Q2
2024-05-30 Årsstämma 2024
2024-05-17 Kvartalsrapport 2024-Q1
2024-03-01 X-dag ordinarie utdelning CSMED 0.00 DKK
2024-02-14 Bokslutskommuniké 2023
2023-12-15 X-dag ordinarie utdelning CSMED 0.00 DKK
2023-07-18 Kvartalsrapport 2023-Q3
2023-05-17 Kvartalsrapport 2023-Q2
2023-04-14 Extra Bolagsstämma 2023
2023-02-17 Kvartalsrapport 2023-Q1
2023-02-14 Årsstämma 2023
2023-02-10 X-dag ordinarie utdelning CSMED 0.00 DKK
2022-11-18 Bokslutskommuniké 2022
2022-08-13 Kvartalsrapport 2022-Q3
2022-05-20 Kvartalsrapport 2022-Q2
2022-02-18 Kvartalsrapport 2022-Q1
2021-12-10 X-dag ordinarie utdelning CSMED 0.00 DKK
2021-12-09 Årsstämma 2022
2021-11-18 Bokslutskommuniké 2021


ListaSpotlight DK
IndustriLäkemedel & Handel
CS Medica är ett danskt medicintekniskt bolag, dedikerat till läkemedelsforskning, utveckling, tillverkning och global kommersialisering. Bolaget blandar vetenskap och natur för att förbättra patienters liv med cannabinoidterapier för smärtlindring, och för att hantera autoimmuna och stressrelaterade symtom. Globalt erbjuder CS Medica CBD-behandlingar över disk (OTC), inklusive patenterade medicinska produkter, MHRA och MDR-registrerade artiklar, under varumärket CANNASEN® eller med egen märkning.
2023-10-31 11:45:18

CS MEDICA received its second-issued patent on its "Nasal Protect Gel," providing protection against pollen, bacteria, viruses, and pollution.

CS MEDICA A/S ("CS MEDICA" or "The Company"), an innovator in the healthcare industry, is proud to announce a significant achievement in its ongoing commitment to revolutionizing categories related to its targeting symptoms of autoimmune diseases and stress-related disorders in this case, Nasal Care & Prevention of hayfever.


The Company received its second issued patent (DK 181405) on Nasal Protect Gel from the esteemed Danish Patent and Trademark Office, validating the uniqueness and originality of the product.  This breakthrough patent represents a milestone for CS MEDICA. It endorses "Nasal Protect Gel" as a groundbreaking solution designed to provide protection and enhance the well-being of individuals experiencing hayfever.

"I'm very proud to confirm that a second member of our portfolio comprising 7 different patent families has been granted. Even though I have a long track record in the pharma industry, it is always different and thrilling when it is your own 'hero' that is considered patentable" states inventor and biochemist Lone Henriksen, CEO and co-founder, CS MEDICA A/S.

Lone Henriksen continues, "The Nasal Protect Gel patent and pending patent applications represent a significant competitive advantage for CS MEDICA, solidifying the Company's position as a challenger and innovator in the field of nasal healthcare solutions. This recognition further strengthens the Company's intellectual property portfolio and growth plans, and particularly the ambition to innovate the healthcare industry".

The background of the Nasal Protect Gel
Nasal congestion can be a distressing and disruptive condition that affects countless individuals worldwide. CS MEDICA's innovative Nasal Protect Gel (https://www.cannasen.com/product/protective-nasal-gel) is a moisturizing gel designed to hydrate and protect nasal mucous membranes from pollen, airborne particles, bacteria, and viruses. With this patent, CS MEDICA seeks to challenge the landscape of nasal care and significantly enhance the quality of life for individuals experiencing nasal congestion and allergies. 

CS MEDICA remains committed to ongoing research and development, aiming to expand the range of effective solutions available to individuals suffering from nasal and allergy conditions and other autoimmune disease symptoms, with its additional patents pending. Find more information about CS MEDICA's patent portfolio here (https://www.cs-medica.com/service/ipr-rights/). 

This disclosure contains information that CS MEDICA A/S is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014) and the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 31-10-2023 11:45 CET.